Deferred Royalty Obligation related to the Sale of Future Royalties Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Deferred Royalty Obligation [Line Items]
Non-cash interest expense on deferred royalty obligation		$ 7,900	$ 5,900	$ 22,380	$ 6,378
Percentage of interest rate amortize liability		18.89%		18.89%
Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Blackstone Life Sciences \| Maximum
Deferred Royalty Obligation [Line Items]
Milestone payment receivable	250,000
2015 License Agreement \| Blackstone Life Sciences
Deferred Royalty Obligation [Line Items]
Transaction costs incurred	3,800
2015 License Agreement \| Blackstone Life Sciences \| Royalty
Deferred Royalty Obligation [Line Items]
Upfront payment received	$ 140,000
Revenue interest percentage	4.00%			4.00%
Amendment 3 2015 License Agreement \| Vaxcyte \| Royalty
Deferred Royalty Obligation [Line Items]
Revenue interest percentage				4.00%